RU2006129464A - Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы - Google Patents
Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы Download PDFInfo
- Publication number
- RU2006129464A RU2006129464A RU2006129464/04A RU2006129464A RU2006129464A RU 2006129464 A RU2006129464 A RU 2006129464A RU 2006129464/04 A RU2006129464/04 A RU 2006129464/04A RU 2006129464 A RU2006129464 A RU 2006129464A RU 2006129464 A RU2006129464 A RU 2006129464A
- Authority
- RU
- Russia
- Prior art keywords
- piperazin
- dihydro
- compound
- quinazolin
- fluorobenzyl
- Prior art date
Links
- 208000015114 central nervous system disease Diseases 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 84
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 20
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 229910052736 halogen Inorganic materials 0.000 claims 14
- -1 2-cyanophenyl Chemical group 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000001188 haloalkyl group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims 3
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 3
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 229910052801 chlorine Inorganic materials 0.000 claims 3
- 239000000460 chlorine Substances 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 229910052731 fluorine Inorganic materials 0.000 claims 3
- 239000011737 fluorine Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 claims 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 3
- PQZIROVGCOLSGN-UHFFFAOYSA-N 1-[(2-methylphenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound CC1=CC=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O PQZIROVGCOLSGN-UHFFFAOYSA-N 0.000 claims 2
- MDKXZMBGVZHRCL-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound FC1=CC=CC(CN2C3=CC=CC(=C3CNC2=O)N2CCNCC2)=C1 MDKXZMBGVZHRCL-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- JVTRZJXFAOQMRA-UHFFFAOYSA-N 1,3-oxazin-2-one Chemical compound O=C1N=CC=CO1 JVTRZJXFAOQMRA-UHFFFAOYSA-N 0.000 claims 1
- AZVOVHHXZRNPDQ-UHFFFAOYSA-N 1-[(2,3-dichlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound ClC1=CC=CC(CN2S(NCC3=C(N4CCNCC4)C=CC=C32)(=O)=O)=C1Cl AZVOVHHXZRNPDQ-UHFFFAOYSA-N 0.000 claims 1
- ZREQQLIQGVXRAC-UHFFFAOYSA-N 1-[(2,3-difluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound FC1=CC=CC(CN2S(NCC3=C(N4CCNCC4)C=CC=C32)(=O)=O)=C1F ZREQQLIQGVXRAC-UHFFFAOYSA-N 0.000 claims 1
- VUOAIRCNUMVRAS-UHFFFAOYSA-N 1-[(2,3-difluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound FC1=CC=CC(CN2C3=CC=CC(=C3CNC2=O)N2CCNCC2)=C1F VUOAIRCNUMVRAS-UHFFFAOYSA-N 0.000 claims 1
- ZNGROUCDEQNFLF-UHFFFAOYSA-N 1-[(2,3-difluorophenyl)methyl]-5-piperazin-1-yl-3-propan-2-yl-4h-quinazolin-2-one Chemical compound O=C1N(C(C)C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC(F)=C1F ZNGROUCDEQNFLF-UHFFFAOYSA-N 0.000 claims 1
- STWAAXRCUIUVEV-UHFFFAOYSA-N 1-[(2,3-difluorophenyl)methyl]-7-ethyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=C(F)C=CC=3)F)C2=CC(CC)=CC=1N1CCNCC1 STWAAXRCUIUVEV-UHFFFAOYSA-N 0.000 claims 1
- BILAYTJFTUXXQI-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound FC1=CC=CC(F)=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O BILAYTJFTUXXQI-UHFFFAOYSA-N 0.000 claims 1
- QLQKILNYYBQJMI-UHFFFAOYSA-N 1-[(2,6-difluorophenyl)methyl]-7-ethyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=CC=CC=3F)F)C2=CC(CC)=CC=1N1CCNCC1 QLQKILNYYBQJMI-UHFFFAOYSA-N 0.000 claims 1
- HKUVDSQISIOHAM-UHFFFAOYSA-N 1-[(2,6-dimethylphenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound CC1=CC=CC(C)=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O HKUVDSQISIOHAM-UHFFFAOYSA-N 0.000 claims 1
- UONKZBXKMRVFEM-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound ClC1=CC=CC=C1CN1S(=O)(=O)NCC2=C(N3CCNCC3)C=CC=C21 UONKZBXKMRVFEM-UHFFFAOYSA-N 0.000 claims 1
- FTMAFOYMGFSILB-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound ClC1=CC=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O FTMAFOYMGFSILB-UHFFFAOYSA-N 0.000 claims 1
- XHNOWLDNPRGPJS-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-7-ethyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=CC=CC=3)Cl)C2=CC(CC)=CC=1N1CCNCC1 XHNOWLDNPRGPJS-UHFFFAOYSA-N 0.000 claims 1
- VUYNORRXANKUQP-UHFFFAOYSA-N 1-[(2-chlorophenyl)methyl]-7-methyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=CC=CC=3)Cl)C2=CC(C)=CC=1N1CCNCC1 VUYNORRXANKUQP-UHFFFAOYSA-N 0.000 claims 1
- HDXMPQDSOJJFFH-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-3-methyl-5-piperazin-1-yl-4h-quinazolin-2-one Chemical compound O=C1N(C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1F HDXMPQDSOJJFFH-UHFFFAOYSA-N 0.000 claims 1
- SSWQMGFCFOHHJV-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound FC1=CC=CC=C1CN1S(=O)(=O)NCC2=C(N3CCNCC3)C=CC=C21 SSWQMGFCFOHHJV-UHFFFAOYSA-N 0.000 claims 1
- ZYFGPTIXKRIOIL-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound FC1=CC=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O ZYFGPTIXKRIOIL-UHFFFAOYSA-N 0.000 claims 1
- NBCLWVINBHJRAF-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-5-piperazin-1-yl-3-propan-2-yl-4h-quinazolin-2-one Chemical compound O=C1N(C(C)C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1F NBCLWVINBHJRAF-UHFFFAOYSA-N 0.000 claims 1
- AEZNVTOBDUUZAK-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-5-piperazin-1-yl-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-one Chemical compound FC1=CC=CC=C1CN1C2=CC(C(F)(F)F)=CC(N3CCNCC3)=C2CNC1=O AEZNVTOBDUUZAK-UHFFFAOYSA-N 0.000 claims 1
- OHPGAQPVVXBWIF-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-7-methyl-5-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-2-one Chemical compound C1CN(C)CCN1C1=CC(C)=CC2=C1CNC(=O)N2CC1=CC=CC=C1F OHPGAQPVVXBWIF-UHFFFAOYSA-N 0.000 claims 1
- DTDSTZIIFOWMRJ-UHFFFAOYSA-N 1-[(2-fluorophenyl)methyl]-7-methyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=CC=CC=3)F)C2=CC(C)=CC=1N1CCNCC1 DTDSTZIIFOWMRJ-UHFFFAOYSA-N 0.000 claims 1
- PWABCZZTBYQOBO-UHFFFAOYSA-N 1-[(2-methylphenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound CC1=CC=CC=C1CN1S(=O)(=O)NCC2=C(N3CCNCC3)C=CC=C21 PWABCZZTBYQOBO-UHFFFAOYSA-N 0.000 claims 1
- DURHUMGTSMUEIR-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1S(=O)(=O)NCC2=C(N3CCNCC3)C=CC=C21 DURHUMGTSMUEIR-UHFFFAOYSA-N 0.000 claims 1
- WFFJMKOOVQAKMJ-UHFFFAOYSA-N 1-[(3,4-dichlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C1=C(Cl)C(Cl)=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O WFFJMKOOVQAKMJ-UHFFFAOYSA-N 0.000 claims 1
- HRKGKFMKQUHQKW-UHFFFAOYSA-N 1-[(3,4-difluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C1=C(F)C(F)=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O HRKGKFMKQUHQKW-UHFFFAOYSA-N 0.000 claims 1
- VLBNZRWSPFXRLV-UHFFFAOYSA-N 1-[(3-chloro-2-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound FC1=C(Cl)C=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O VLBNZRWSPFXRLV-UHFFFAOYSA-N 0.000 claims 1
- AFGKWQWJPYQERS-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound ClC1=CC=CC(CN2S(NCC3=C(N4CCNCC4)C=CC=C32)(=O)=O)=C1 AFGKWQWJPYQERS-UHFFFAOYSA-N 0.000 claims 1
- CNEXRAAANDGMPR-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound ClC1=CC=CC(CN2C3=CC=CC(=C3CNC2=O)N2CCNCC2)=C1 CNEXRAAANDGMPR-UHFFFAOYSA-N 0.000 claims 1
- ZSQIPLBUCUIQEW-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-5-piperazin-1-yl-3-propan-2-yl-4h-quinazolin-2-one Chemical compound O=C1N(C(C)C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC(Cl)=C1 ZSQIPLBUCUIQEW-UHFFFAOYSA-N 0.000 claims 1
- WFBSULFTDHFZCY-UHFFFAOYSA-N 1-[(3-chlorophenyl)methyl]-7-ethyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C=C(Cl)C=CC=3)C2=CC(CC)=CC=1N1CCNCC1 WFBSULFTDHFZCY-UHFFFAOYSA-N 0.000 claims 1
- PJDFWQSESQKQNK-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-3-methyl-5-piperazin-1-yl-4h-quinazolin-2-one Chemical compound O=C1N(C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC(F)=C1 PJDFWQSESQKQNK-UHFFFAOYSA-N 0.000 claims 1
- COSPLTUHJCIOQN-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-(4-methylpiperazin-1-yl)-3,4-dihydroquinazolin-2-one Chemical compound C1CN(C)CCN1C1=CC=CC2=C1CNC(=O)N2CC1=CC=CC(F)=C1 COSPLTUHJCIOQN-UHFFFAOYSA-N 0.000 claims 1
- VXZJWJHIPBYIQW-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound FC1=CC=CC(CN2S(NCC3=C(N4CCNCC4)C=CC=C32)(=O)=O)=C1 VXZJWJHIPBYIQW-UHFFFAOYSA-N 0.000 claims 1
- WJMOBCPZXTZDDM-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-piperazin-1-yl-3-propan-2-yl-4h-quinazolin-2-one Chemical compound O=C1N(C(C)C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC(F)=C1 WJMOBCPZXTZDDM-UHFFFAOYSA-N 0.000 claims 1
- CZRPTAXTPDFGFM-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-piperazin-1-yl-4h-3,1-benzoxazin-2-one Chemical compound FC1=CC=CC(CN2C3=CC=CC(=C3COC2=O)N2CCNCC2)=C1 CZRPTAXTPDFGFM-UHFFFAOYSA-N 0.000 claims 1
- KDPYLJANQNSJEK-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-5-piperazin-1-yl-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-one Chemical compound FC1=CC=CC(CN2C3=CC(=CC(=C3CNC2=O)N2CCNCC2)C(F)(F)F)=C1 KDPYLJANQNSJEK-UHFFFAOYSA-N 0.000 claims 1
- BKDZLPRBGFRWFR-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-7-methoxy-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C=C(F)C=CC=3)C2=CC(OC)=CC=1N1CCNCC1 BKDZLPRBGFRWFR-UHFFFAOYSA-N 0.000 claims 1
- ICFIZPGUDQIOQG-UHFFFAOYSA-N 1-[(3-fluorophenyl)methyl]-7-methyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C=C(F)C=CC=3)C2=CC(C)=CC=1N1CCNCC1 ICFIZPGUDQIOQG-UHFFFAOYSA-N 0.000 claims 1
- LGRNEPWCKFRPPA-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound C1=CC(Cl)=CC=C1CN1S(=O)(=O)NCC2=C(N3CCNCC3)C=CC=C21 LGRNEPWCKFRPPA-UHFFFAOYSA-N 0.000 claims 1
- WGZRGWPASCNABE-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C1=CC(Cl)=CC=C1CN1C2=CC=CC(N3CCNCC3)=C2CNC1=O WGZRGWPASCNABE-UHFFFAOYSA-N 0.000 claims 1
- WZCIGDURTXEHFY-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-3-methyl-5-piperazin-1-yl-4h-quinazolin-2-one Chemical compound O=C1N(C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=C(F)C=C1 WZCIGDURTXEHFY-UHFFFAOYSA-N 0.000 claims 1
- NEJULOZWVLPODE-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound C1=CC(F)=CC=C1CN1S(=O)(=O)NCC2=C(N3CCNCC3)C=CC=C21 NEJULOZWVLPODE-UHFFFAOYSA-N 0.000 claims 1
- VTFBLDKNJLBVPJ-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]-5-piperazin-1-yl-3-propan-2-yl-4h-quinazolin-2-one Chemical compound O=C1N(C(C)C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=C(F)C=C1 VTFBLDKNJLBVPJ-UHFFFAOYSA-N 0.000 claims 1
- XGYMOMRCZKFJGG-UHFFFAOYSA-N 1-benzyl-3-ethyl-5-piperazin-1-yl-4h-quinazolin-2-one Chemical compound O=C1N(CC)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 XGYMOMRCZKFJGG-UHFFFAOYSA-N 0.000 claims 1
- NDGXDCQTFHASLS-UHFFFAOYSA-N 1-benzyl-3-methyl-5-piperazin-1-yl-4h-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound O=S1(=O)N(C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 NDGXDCQTFHASLS-UHFFFAOYSA-N 0.000 claims 1
- VMHWBQZTFACGHZ-UHFFFAOYSA-N 1-benzyl-3-methyl-5-piperazin-1-yl-4h-quinazolin-2-one Chemical compound O=C1N(C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 VMHWBQZTFACGHZ-UHFFFAOYSA-N 0.000 claims 1
- LQXBXVDFUCCDJA-UHFFFAOYSA-N 1-benzyl-5-piperazin-1-yl-3,4-dihydro-2$l^{6},1,3-benzothiadiazine 2,2-dioxide Chemical compound O=S1(=O)NCC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 LQXBXVDFUCCDJA-UHFFFAOYSA-N 0.000 claims 1
- QDEHEDMGJOKOIM-UHFFFAOYSA-N 1-benzyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound O=C1NCC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 QDEHEDMGJOKOIM-UHFFFAOYSA-N 0.000 claims 1
- ULQQHZGKMZWFDD-UHFFFAOYSA-N 1-benzyl-5-piperazin-1-yl-3-propan-2-yl-4h-quinazolin-2-one Chemical compound O=C1N(C(C)C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 ULQQHZGKMZWFDD-UHFFFAOYSA-N 0.000 claims 1
- MXGLXHPGMCBMAK-UHFFFAOYSA-N 1-benzyl-5-piperazin-1-yl-4h-3,1-benzoxazin-2-one Chemical compound O=C1OCC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC=C1 MXGLXHPGMCBMAK-UHFFFAOYSA-N 0.000 claims 1
- RPPKAAXCQQTHKG-UHFFFAOYSA-N 1-benzyl-5-piperazin-1-yl-7-(trifluoromethyl)-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C=CC=CC=3)C2=CC(C(F)(F)F)=CC=1N1CCNCC1 RPPKAAXCQQTHKG-UHFFFAOYSA-N 0.000 claims 1
- OAMKXXZOKAQMFE-UHFFFAOYSA-N 1-benzyl-6-fluoro-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound O=C1NCC2=C(N3CCNCC3)C(F)=CC=C2N1CC1=CC=CC=C1 OAMKXXZOKAQMFE-UHFFFAOYSA-N 0.000 claims 1
- RVGXECDQOALXBM-UHFFFAOYSA-N 1-benzyl-7-ethyl-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C=CC=CC=3)C2=CC(CC)=CC=1N1CCNCC1 RVGXECDQOALXBM-UHFFFAOYSA-N 0.000 claims 1
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- HSBCWXOUIRFTQI-UHFFFAOYSA-N 3-[(3-methyl-2-oxo-5-piperazin-1-yl-4h-quinazolin-1-yl)methyl]benzonitrile Chemical compound O=C1N(C)CC2=C(N3CCNCC3)C=CC=C2N1CC1=CC=CC(C#N)=C1 HSBCWXOUIRFTQI-UHFFFAOYSA-N 0.000 claims 1
- 125000003852 3-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C(Cl)=C1[H])C([H])([H])* 0.000 claims 1
- 125000004176 4-fluorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1F)C([H])([H])* 0.000 claims 1
- MWGFWHUKFODITF-UHFFFAOYSA-N 7-ethyl-1-[(2-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=CC=CC=3)F)C2=CC(CC)=CC=1N1CCNCC1 MWGFWHUKFODITF-UHFFFAOYSA-N 0.000 claims 1
- NYFQYWSXAOMRLV-UHFFFAOYSA-N 7-ethyl-1-[(3-fluorophenyl)methyl]-5-piperazin-1-yl-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C=C(F)C=CC=3)C2=CC(CC)=CC=1N1CCNCC1 NYFQYWSXAOMRLV-UHFFFAOYSA-N 0.000 claims 1
- OCLPRALFZDEMMK-UHFFFAOYSA-N 7-ethyl-5-piperazin-1-yl-1-[[2-(trifluoromethyl)phenyl]methyl]-3,4-dihydroquinazolin-2-one Chemical compound C=12CNC(=O)N(CC=3C(=CC=CC=3)C(F)(F)F)C2=CC(CC)=CC=1N1CCNCC1 OCLPRALFZDEMMK-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004404 heteroalkyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D265/18—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/15—Six-membered rings
- C07D285/16—Thiadiazines; Hydrogenated thiadiazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53708004P | 2004-01-16 | 2004-01-16 | |
| US60/537,080 | 2004-01-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2006129464A true RU2006129464A (ru) | 2008-02-27 |
Family
ID=34794441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006129464/04A RU2006129464A (ru) | 2004-01-16 | 2005-01-07 | Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US7196087B2 (enExample) |
| EP (1) | EP1708713B1 (enExample) |
| JP (1) | JP4533391B2 (enExample) |
| KR (1) | KR100843053B1 (enExample) |
| CN (1) | CN1909909B (enExample) |
| AR (1) | AR047958A1 (enExample) |
| AT (1) | ATE388712T1 (enExample) |
| AU (1) | AU2005205016B2 (enExample) |
| BR (1) | BRPI0506909A (enExample) |
| CA (1) | CA2552681A1 (enExample) |
| CO (1) | CO5700763A2 (enExample) |
| DE (1) | DE602005005298T2 (enExample) |
| ES (1) | ES2302174T3 (enExample) |
| IL (1) | IL176631A0 (enExample) |
| NO (1) | NO20062791L (enExample) |
| RU (1) | RU2006129464A (enExample) |
| TW (1) | TW200530222A (enExample) |
| WO (1) | WO2005067933A1 (enExample) |
| ZA (1) | ZA200605434B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006037482A2 (en) * | 2004-09-30 | 2006-04-13 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cognitive disorders |
| US7713954B2 (en) * | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| WO2006065686A2 (en) * | 2004-12-13 | 2006-06-22 | Galileo Pharmaceuticals, Inc. | Spiro derivatives as lipoxygenase inhibitors |
| CN101263136A (zh) * | 2005-07-13 | 2008-09-10 | 弗·哈夫曼-拉罗切有限公司 | 作为5-ht6、5-ht24的苯并咪唑衍生物 |
| KR100817538B1 (ko) * | 2006-07-05 | 2008-03-27 | 한국화학연구원 | 신규 치환된―１ｈ―퀴나졸린―２,４―디온 유도체, 이의제조방법 및 이를 함유하는 약학적 조성물 |
| RU2009113612A (ru) * | 2006-09-11 | 2010-10-20 | Н.В. Органон (Nl) | Ацетамидные производные хиназолинона и изохинолинона |
| WO2008073958A2 (en) | 2006-12-12 | 2008-06-19 | Wyeth | Substituted benzothiadiazinedioxide derivatives and methods of their use |
| KR20110036583A (ko) * | 2008-06-20 | 2011-04-07 | 로타팜 에스.피.에이. | 6-1ｈ-이미다조-퀴나졸린 및 퀴놀린 유도체, 신규 ｍａｏ 억제제 및 이미다졸린 수용체 리간드 |
| MX2011001925A (es) | 2008-09-08 | 2011-04-05 | Hoffmann La Roche | Benzoxazinas 5-sustituidas. |
| WO2011144059A1 (zh) | 2010-05-21 | 2011-11-24 | 深圳信立泰药业股份有限公司 | 一种稠环喹唑啉类衍生物及其应用 |
| CA3043319A1 (en) | 2016-11-15 | 2018-05-24 | Temple University-Of The Commonwealth System Of Higher Education | Modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
| US12247015B2 (en) | 2019-04-29 | 2025-03-11 | Solent Therapeutics, Llc | 3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2 |
| JP7696354B2 (ja) * | 2019-10-21 | 2025-06-20 | アライリオン インコーポレイテッド | 睡眠障害の治療のためのＨ１および５－ＨＴ２Ａ受容体調節物質としての３－（４－（１１Ｈ－ジベンゾ［ｂ，ｅ］［１，４］アゼピン－６－イル）ピペラジン－１－イル）－プロパン酸誘導体および３－（４－（ジベンゾ［ｂ，ｆ］［１，４］オキサゼピン／チアゼピン／ジアゼピン－１１－イル）ピペラジン－１－イル）－プロパン酸誘導体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3642791A (en) * | 1969-08-13 | 1972-02-15 | Sandoz Ag | Morpholino-1-substituted-2(1h)-quinazolinones |
| JPS5271483A (en) * | 1975-12-11 | 1977-06-14 | Sumitomo Chem Co Ltd | Synthesis of 2(1h)-quinazolinone derivatives |
| CN1015459B (zh) * | 1985-06-06 | 1992-02-12 | 田边制药株式会社 | 喹唑啉酮化合物的制备方法 |
| GR1000821B (el) * | 1988-11-22 | 1993-01-25 | Tanabe Seiyaku Co | Μεθοδος παραγωγης παραγωγων κιναζολινονης. |
| AU6908398A (en) | 1996-10-28 | 1998-05-22 | Versicor Inc | Fused 2,4-pyrimidinedione combinatorial libraries and biologically active fused 2,4-pyramidinediones |
| WO1998042688A1 (fr) | 1997-03-26 | 1998-10-01 | Sumitomo Pharmaceuticals Co., Ltd. | Derives de 4-arylmethylene-1,4-dihydro-2h-azine |
| ATE239000T1 (de) | 1997-10-28 | 2003-05-15 | Warner Lambert Co | 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel |
| WO1999037643A1 (en) * | 1998-01-26 | 1999-07-29 | Yamanouchi Pharmaceutical Co., Ltd. | Novel benzene-fused heterocyclic derivatives or salts thereof |
| EP1228043B1 (en) * | 1999-11-05 | 2005-01-12 | SmithKline Beecham plc | Isoquinoline and quinazoline deivatives having a combined 5ht1a, 5ht1b and 5ht1d receptor activity |
| WO2001037837A1 (en) | 1999-11-23 | 2001-05-31 | Smithkline Beecham Corporation | 3,4-DIHYDRO-(1H)-QUINAZOLIN-2-ONES AND THEIR USE AS CSBP/p38 KINASE INHIBITORS |
| WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
| AU2002246677B2 (en) * | 2000-12-20 | 2006-11-16 | Merck Sharp & Dohme Corp. | (Halo-Benzo Carbonyl)Heterocyclo Fused Phenyl p38 Kinase Inhibiting Agents |
| US6998408B2 (en) * | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| ATE331707T1 (de) * | 2001-06-15 | 2006-07-15 | Hoffmann La Roche | 4 piperazinylindolderivate mit affinität zum 5- ht6-rezeptor |
| GB0203804D0 (en) * | 2002-02-18 | 2002-04-03 | Glaxo Group Ltd | Compounds |
| CA2485136C (en) * | 2002-05-13 | 2011-12-20 | F. Hoffmann-La Roche Ag | Benzoxazine derivatives as 5-ht6 modulators and uses thereof |
-
2005
- 2005-01-07 RU RU2006129464/04A patent/RU2006129464A/ru unknown
- 2005-01-07 AT AT05700747T patent/ATE388712T1/de active
- 2005-01-07 CA CA002552681A patent/CA2552681A1/en not_active Abandoned
- 2005-01-07 BR BRPI0506909-2A patent/BRPI0506909A/pt not_active IP Right Cessation
- 2005-01-07 KR KR1020067014320A patent/KR100843053B1/ko not_active Expired - Fee Related
- 2005-01-07 CN CN2005800026123A patent/CN1909909B/zh not_active Expired - Fee Related
- 2005-01-07 JP JP2006548231A patent/JP4533391B2/ja not_active Expired - Fee Related
- 2005-01-07 WO PCT/EP2005/000095 patent/WO2005067933A1/en not_active Ceased
- 2005-01-07 DE DE602005005298T patent/DE602005005298T2/de not_active Expired - Lifetime
- 2005-01-07 ES ES05700747T patent/ES2302174T3/es not_active Expired - Lifetime
- 2005-01-07 EP EP05700747A patent/EP1708713B1/en not_active Expired - Lifetime
- 2005-01-07 AU AU2005205016A patent/AU2005205016B2/en not_active Ceased
- 2005-01-13 AR ARP050100106A patent/AR047958A1/es not_active Application Discontinuation
- 2005-01-13 TW TW094101029A patent/TW200530222A/zh unknown
- 2005-01-14 US US11/035,506 patent/US7196087B2/en not_active Expired - Fee Related
-
2006
- 2006-06-15 NO NO20062791A patent/NO20062791L/no not_active Application Discontinuation
- 2006-06-29 IL IL176631A patent/IL176631A0/en unknown
- 2006-06-30 ZA ZA200605434A patent/ZA200605434B/en unknown
- 2006-07-13 CO CO06068258A patent/CO5700763A2/es not_active Application Discontinuation
-
2007
- 2007-02-07 US US11/703,424 patent/US7365063B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| NO20062791L (no) | 2006-08-01 |
| AU2005205016A1 (en) | 2005-07-28 |
| ES2302174T3 (es) | 2008-07-01 |
| US7365063B2 (en) | 2008-04-29 |
| CA2552681A1 (en) | 2005-07-28 |
| JP2007517826A (ja) | 2007-07-05 |
| ATE388712T1 (de) | 2008-03-15 |
| JP4533391B2 (ja) | 2010-09-01 |
| CO5700763A2 (es) | 2006-11-30 |
| DE602005005298D1 (de) | 2008-04-24 |
| WO2005067933A1 (en) | 2005-07-28 |
| KR100843053B1 (ko) | 2008-07-01 |
| ZA200605434B (en) | 2008-02-27 |
| AR047958A1 (es) | 2006-03-15 |
| KR20060126720A (ko) | 2006-12-08 |
| EP1708713B1 (en) | 2008-03-12 |
| US20070149510A1 (en) | 2007-06-28 |
| AU2005205016B2 (en) | 2010-07-15 |
| CN1909909B (zh) | 2010-12-15 |
| US20050165001A1 (en) | 2005-07-28 |
| CN1909909A (zh) | 2007-02-07 |
| US7196087B2 (en) | 2007-03-27 |
| BRPI0506909A (pt) | 2007-05-29 |
| TW200530222A (en) | 2005-09-16 |
| IL176631A0 (en) | 2006-10-31 |
| DE602005005298T2 (de) | 2009-03-12 |
| EP1708713A1 (en) | 2006-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2006129464A (ru) | Производные 1-бензил-5-пиперазин-1-ил-3, 4-дигидро-1н-хиназолин-2-она и соответствующие производные 1н-бензо (1, 2, 6) тиадиазин-2, 2-диоксида и 1, 4-дигидробензо (1, 3)оксазин-2-она в качестве модуляторов рецептора 5-гидрокситриптамина (5нт) для лечения заболевания центральной нервной системы | |
| RU2007143966A (ru) | Конденсированные гетероциклические соединения | |
| JP2005533024A5 (enExample) | ||
| RU2005117965A (ru) | Замещенные бензоксазиноны и их применение | |
| RU2350616C2 (ru) | Производные пиразоло- и имидазопиримидина | |
| JP2002534519A5 (enExample) | ||
| RU2004127925A (ru) | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек | |
| CA2526430A1 (en) | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | |
| RU96111418A (ru) | ПРОИЗВОДНЫЕ ПИРИМИДИНДИОНА, ПИРИМИДИНТРИОНА, ТРИАЗИНДИОНА, ТЕТРАГИДРОХИНАЗОЛИНДИОНА В КАЧЕСТВЕ АНТАГОНИСТОВ α1 АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ | |
| JP2007517044A5 (enExample) | ||
| RU2005123484A (ru) | Новые производные пиридазин-3(2н)-она | |
| JP2005535586A5 (enExample) | ||
| JP2005538955A5 (enExample) | ||
| JP2005503345A5 (enExample) | ||
| JP2008535930A5 (enExample) | ||
| JP2003511384A5 (enExample) | ||
| JP2007510689A5 (enExample) | ||
| JP2005503356A5 (enExample) | ||
| SI20269B (sl) | Derivati acil-piperazinil-pirimidinov, njihova priprava in uporaba kot zdravila | |
| RU2009133807A (ru) | Соединения амино-5-[замещенного-4-(дифторметокси)фенил]-5-фенилимидазолона в качестве ингибиторов бета-секретазы | |
| JP2013519724A5 (enExample) | ||
| JP2011528034A5 (enExample) | ||
| IE912114A1 (en) | Novel pyrimidine derivatives which are angiotensin ii¹receptor antagonists, their methods of preparation and¹pharmaceutical compositions in which they are present | |
| JP2007520440A5 (enExample) | ||
| EE200300455A (et) | Imidasopürimidiini derivaadid, nende valmistamisprotsess ja kasutamine ning farmatseutiline kompositsioon |